<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="142991">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01992484</url>
  </required_header>
  <id_info>
    <org_study_id>ATLANTIS-ACS</org_study_id>
    <nct_id>NCT01992484</nct_id>
  </id_info>
  <brief_title>Platelet Function in Patients With an Acute Coronary Syndrome</brief_title>
  <acronym>ATLANTIS-ACS</acronym>
  <official_title>Association Between the Antiplatelet Drug Efficacy/Safety and Platelet Function in Patients Treated With Novel Platelet Inhibitors Due to an Acute Coronary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <authority>Austria: Ethikkommission</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aims of the study are to:

        -  explore whether platelet reactivity in patients treated wih novel platelet inhibitors
           is associated with clinical outcome

        -  investigate whether a therapeutic window exist for novel platelet inhibitors

        -  investigate the incidence of adverse events under treatment with novel platelet
           inhibitors in the real life clinical scenario

        -  investigate the association between genetic polymorphisms, inflammation, platelet
           reactivity and clinical outcome

        -  investigate synergistic effects between aspirin and novel platelet inhibitors
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Net clinical benefit.</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>A composite of MACE and BARC=&gt;2 bleedings.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MACE and Major bleeding</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>MACE: the composite of stent thrombosis, cardiac death and myocardial infarction.
Major Bleeding: BARC =&gt;2, TIMI major, GUSTO moderate-severe-life threatening.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>single endpoints of acute coronary syndrome, myocardial infarction, cardiac death, all-cause death, urgent vessel revascularization (PCI or CABG), stroke.</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Acute Coronary Syndrome (ACS)</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients presenting with an acute coronary syndrome
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Acute coronary syndrome at admission

          -  Planned treatment with novel platelet inhibitors

          -  Age &gt;18

        Exclusion Criteria:

        * Participation in interventional trials
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jolanta M Siller-Matula, PD MD PhD</last_name>
    <phone>0043 1 404004614</phone>
    <email>jolanta.siller-matula@meduniwien.ac.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical Univerity of Vienna, Department of Cardiology</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jolanta M Siller-Matula, PD MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Georg Delle-Karth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 19, 2013</lastchanged_date>
  <firstreceived_date>November 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Jolanta Siller-Matula</investigator_full_name>
    <investigator_title>PD Dr.med. PhD</investigator_title>
  </responsible_party>
  <keyword>platelets, Acute coronary Syndrome (ACS), prasugrel, ticagrelor, aspirin</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Platelet Aggregation Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
